Feeds:
Posts
Comments

Posts Tagged ‘Brilinta’

TODAY’S NEWS

How to do dumb insider trading – a lesson.

Experimental Plavix competitor Brilinta showing improved efficacy in ACS stent patients.

Enbrel competitor Stelera shows greater efficacy in psoriasis treatment.

Obesity leveling off in U.S., but Diabetes is killing the economy.

RECOMMENDED

Management development. From full curriculum planning to workshops to targeted courses, we have the providers you need in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Looking to get started in social media, or find out where all the pharma social media resources are? Start here.

JUST FOR FUN

Visual awesomeness, part 2 – another spectacular view of Martian landforms.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Tune in TODAY – I’ll be doing a live on-line interview on Social Media in Pharma with Paul Chaney – starts at 1 pm EST (just use the call-in number – see the link). Also, here’s a page on my site with all sorts of social media resources for pharma professionals: http://bit.ly/socialrx

TODAY’S NEWS

AstraZeneca’s new Plavix-competitor Brilinta expected to go big – It is the first antiplatelet drug to demonstrate it can reduce cardiovascular (CV) deaths compared to the current gold standard treatment, Plavix (clopidogrel) in patients with acute coronary syndromes (ACS). Results of the 18600 patient Phase III PLATO trial comparing the two drugs, were revealed at the recent European Society of Cardiology (ESC) Congress in Barcelona…Platelet expert Dr Victor Serebruany agreed the mortality data is ”marvelous,” with 107 extra lives saved compared to Plavix. “It has never been seen before and no one expected it,” he saidmore

Big oncology news (approval for new lymphoma drug) today – Allos Therapeutics Inc. said Friday that regulators approved its injectable drug Folotyn as a treatment for peripheral T-cell lymphoma, a group of rare, agressive blood cancers, sending its shares soaring. Allos said the Food and Drug Administration granted accelerated approval, allowing the company to market Folotyn for use in patients whose cancer has returned or not responded to previous treatment. Allos expects to begin selling the drug in October. There are no drugs on the market that treat peripheral T-cell lymphoma, Allos saidmore Plus, some future hope from Roche on melanoma?

So the FDA is finally going to start wresting with social media in pharma! Here’s what companies need to do to prepare for the hearing this fall. And here also.

This bothers me.

RECOMMENDED

Compliance training. When y0u need compliance training development partners for your employees, we’ve got g. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

An interview with the President and CEO of Sanofi-Aventis US (Gregory Irace), on the big changes they are undergoing to re-structure the company, and the way they deliver information.

Coming up next month:

DigitalPharma

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »